Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Josh Rancourt"'
Autor:
Inmaculada de la Torre, Masayoshi Harigai, Joel M Kremer, Edward C Keystone, Maher Issa, Christina Dickson, Josh Rancourt, Thomas Melby, Yoshitaka Isaka, Anabela Cardoso, Chadi Saifan
Publikováno v:
RMD Open, Vol 6, Iss 3 (2020)
Objective To characterise changes in selected haematological parameters following once-daily oral baricitinib dosing.Methods Data were pooled from eight randomised clinical trials (four phase 3, three phase 2, one phase 1b) and one long-term extensio
Externí odkaz:
https://doaj.org/article/a4233ce845114923aee5548ee591ccb3
Autor:
Yoshitaka Isaka, Inmaculada de la Torre, Tom W J Huizinga, Maher Issa, Masayoshi Harigai, C. Dickson, Joel M. Kremer, Ronald F. van Vollenhoven, Jonathan Kay, Jon T. Giles, Anabela Cardoso, Edward C. Keystone, Thomas Melby, Chadi Saifan, Josh Rancourt
Publikováno v:
RMD open, 6(3):e001370. BMJ Publishing Group
RMD Open, 6(3):e001370. BMJ Publishing Group
RMD Open
RMD Open, Vol 6, Iss 3 (2020)
RMD Open, 6(3). BMJ PUBLISHING GROUP
Kay, J, Harigai, M, Rancourt, J, Dickson, C, Melby, T, Issa, M, De La Torre, I, Isaka, Y, Cardoso, A, Saifan, C, Keystone, E C, Van Vollenhoven, R F, Giles, J T, Huizinga, T W J & Kremer, J M 2020, ' Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib ', RMD Open, vol. 6, no. 3, e001370 . https://doi.org/10.1136/rmdopen-2020-001370
RMD Open, 6(3):e001370. BMJ Publishing Group
RMD Open
RMD Open, Vol 6, Iss 3 (2020)
RMD Open, 6(3). BMJ PUBLISHING GROUP
Kay, J, Harigai, M, Rancourt, J, Dickson, C, Melby, T, Issa, M, De La Torre, I, Isaka, Y, Cardoso, A, Saifan, C, Keystone, E C, Van Vollenhoven, R F, Giles, J T, Huizinga, T W J & Kremer, J M 2020, ' Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib ', RMD Open, vol. 6, no. 3, e001370 . https://doi.org/10.1136/rmdopen-2020-001370
ObjectiveTo characterise changes in selected haematological parameters following once-daily oral baricitinib dosing.MethodsData were pooled from eight randomised clinical trials (four phase 3, three phase 2, one phase 1b) and one long-term extension.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f8d0d4734d836240ee902e1db4d772e
https://doi.org/10.1136/rmdopen-2020-001370
https://doi.org/10.1136/rmdopen-2020-001370
